TEST

The CEO Sessions

An opportunity for investors and advisers to hear directly from listed company CEOs on company strategy, prospects, and performance.

ASX and FNN are proud to present a program of forums for investors. Hear CEOs and senior representatives of listed companies present their investment story.
Join them afterwards for an informal meet and greet session, with lunch provided.


Register your attendance for an upcoming event

Upcoming Events in Sydney

15 November 2016

Ian Macoun
Pinnacle Investment Management Group Ltd (ASX:PNI)
Ian Macoun, MD

Pinnacle is a leading Australian-based multi-affiliate investment management firm. Our mission is to establish, grow and support a diverse stable of world-class investment management firms.

Pinnacle currently consists of seven investment affiliates that collectively manage over A$21 billion in assets across a diverse range of asset classes. Pinnacle provides distribution and other support services to its affiliates and a select number of aligned investment managers.

Dr Chris Hart
Oventus Medical Ltd (ASX:BRN)
Dr Chris Hart, Founder

Oventus Medical Ltd. (ASX: OVN) is a medical device sleep apnoea and snoring disorder company. Having established a platform for accelerated growth following the successful $12 million IPO capital raising and is already reporting encouraging early revenue.

Oventus is focused on developing and producing oral appliances to treat obstructive sleep apnoea and snoring, especially in people who cannot be, or are not effectively treated with existing devices or therapies.

Nicholas Andrew
Magontec Ltd (ASX:OEC)
Nicholas Andrew, Executive Chairman

Magontec is a manufacturer and recycler of magnesium alloys with primary production, recycling and sales operations in China, Germany and Romania and distribution activities in the USA, Japan and Taiwan. The company also manufacturers value-add downstream products that are die cast and extruded.

In 2017 Magontec will commence production at the World’s most environmentally friendly magnesium alloy cast house at Golmud in Qinghai Province PRC

Simon Wilkinson
Innate Immunotherapeutics Ltd (ASX:PNR)
Simon Wilkinson, CEO

Innate Immunotherapeutics (ASX:IIL) is a clinical stage biotech company with an exciting technology that targets the human innate immune system. The company is currently conducting a Phase 2B efficacy trial of a drug candidate, MIS416, to treat secondary progressive multiple sclerosis.

There are currently no safe and effective treatments for this progressive and highly disabling form of MS. Innate has received strong partnering interest from major Pharma companies and expects that a successful trial result in the first half of next year will quickly translate into a major corporate transaction.

 

Dexus at The CEO Sessions

Crowd at The CEO Sessions

Investor Audience at The CEO Sessions


Latest Videos


1 Sep 2010

Index Options

September ‘10 - Andy Semple explains the differences between stock and index options and the advantages of trading an option with broad based exposure.

30 Jul 2010

Long dated calls

August ‘10 - Andy Semple reminds us of all about the usefulness of a simple long dated call. Less risk than owning the underlying stock with built in protection at the strike price. Why not use a long dated call for your next buy and hold trade?

3 Jun 2010

Covered combos

June ‘10 - Andy Semple explains how to brings in two premiums writing out of the money puts and calls, potentially selling your stock for more or adding to your position for less than the current price.

5 May 2010

Bull Put Spreads

May ‘10 - Andy Semple explains how the Bull spread delivers a similar return to the protected buy write for a whole lot less capital.

30 Apr 2010

Time to gear into Shares

May ‘10 - 'AAA' Commercial Mortgages, MD, John Macalyk explains the pros & cons, citing Mike Tyson as inspiration.

1 Apr 2010

Margin Lending & Options

April ‘10 - Andy Semple explains why sensible gearing is a must and how to use it as a line of credit for options trading.

11 Feb 2010

Working capital alternatives

February ‘10 - 'AAA' Commercial Mortgages, MD, John Macalyk explains what’s available and how to qualify.

29 Jan 2010

Timing your option trades

January 2010 - Andy Semple talks trend trading basics and how to use these to time your option trades

10 Nov 2009

Direct property in SMSF

November 2009 - 'AAA' Commercial Mortgages, MD, John Macalyk explains the rules and advantages.

2 Nov 2009

Exchange Traded Options

November 09 – Andy Semple takes us through a Buy & Write on ANZ for Dec expiry with a 6.3% return if exercised for 52 days

2 Sep 2009

Construction Finance

September 2009 - 'AAA' Commercial Mortgages, MD, John Macalyk shows you where to get construction finance and the costs.

20 Jul 2009

Commercial property valuation

July 2009 - MD, John Macalyk, 'AAA' Commercial Mortgages takes us through the valuation process using an example of a commercial property in Randwick, NSW as a case in point.

17 Jun 2009

Commercial property opportunities - June 09

MD, John Macalyk, 'AAA' Commercial Mortgages shares his considerable experience, looks at several properties and explains why he favours variable over fixed rate funding.